THE PNOC DIFFERENCE
PNOC's highly ambitious, high reward research will change the course of pediatric brain cancer and save and improve children’s lives.
Through a ground-breaking global collaboration across 37 clinical sites around the globe, PNOC brings together 225+ researchers and clinicians dedicated to bringing new therapies to children and young adults with brain tumors. The intent is to be collaborative, forward thinking, strategic, and efficient in developing clinical trials for the highest unmet need patients.
PNOC RESEARCH GROUPS
PNOC's disease specific research groups are accelerating progress. PNOC has dedicated research groups for: Low grade Glioma, Diffuse Midline Glioma/High grade Glioma (including DIPG), Medulloblastoma, Atypical Teratoid Rhabdoid Tumors (ATRT), Craniopharyngioma, Ependymoma, Germ Cell Tumors, Immunotherapy as well as Imaging, and DEI (Diversity, Equity, and Inclusion). Watch our disease specific informational webinars with PNOC experts.
Traditional brain cancer protocols do not mandate tissue samples, and apply blanket treatments which can lead to ineffective treatments and serious adverse side effects. PNOC trials are based on precision medicine and immunotherapy, because we understand that each tumor is as unique as each child.
OPEN SOURCE DATA SHARING
Through PNOC's pioneering partnership with the Children’s Brain Tumor Network (CBTN), tissue samples and data are available in real time to researchers around the world. Through a suite of cloud-based data platforms CBTN has co-developed, researchers can access these rich collections of brain tumor data from anywhere in the world.
MARCH 2022 CAMPAIGN LAUNCH: THE AT/RT REGISTRY, THE FIRST STEP TOWARDS AT/RT BREAKTHROUGHS
The PNOC AT/RT Working Group is committed to changing the course of history for children diagnosed with AT/RT through data driven discovery. The AT/RT Registry is an essential step towards treatment breakthroughs. Click to learn more and donate to support the AT/RT Registry today!
PNOC has treated over 500 children with cutting edge treatments.